Protalix BioTherapeutics, Inc.
HealthcareAMEX:PLX · New York Stock Exchange American
+$0.04 today
Vol 0.25M · Avg 0.83M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-13.7%
avg 164.6%
ROIC
-9.6%
avg -34.1%
ROA
-8.0%
avg -22.1%
Analysis
ROA is currently the strongest return metric at -8.0% versus its period average of -22.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Dror Bashan | President, Chief Executive Officer & Director | $807,902.00 | — | 59 | $188,516.00 | 0.23% |
Yaron Naos | SVP & COO | $418,139.00 | — | 62 | $50,000.00 | 0.06% |
Gilad Mamlok | Senior VP, CFO Treasurer & Secretary | $309,415.00 | — | 58 | $0.00 | <0.01% |
Yael Fellous | Vice President of Human Resources | — | — | — | $35,115.00 | 0.04% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$101,360.00
Sells
1
$314.16
Net Sentiment
+$101,045.84
Net buying
Most Active
Bashan Dror
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Dec 19, 2025 | Bashan Dror Direct | Buy | 56.0K | $1.81 | $101,360.00 | |
| Nov 18, 2025 | Bar-Shalev Amos Direct | Sell | 168 | $1.87 | $314.16 |
Analysis
Insiders reported 1 buys worth $101,360.00 and 1 sells worth $314.16 over the last 12 months. That adds up to net buying of $101,045.84. Bashan Dror was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | -27.1% (13yr)1 analysts |
| Revenue | N/A | N/A | -49.8% | +23.4% (13yr)1 analysts |
| Net Income | N/A | N/A | N/A | -28.6% (13yr)1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -49.8% over three years. Forward estimates point to Revenue at +23.4% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
$1.12B
Genfit S.A.
GNFT
$445.68M
OmniAb, Inc.
NASDAQ:OABI
$270.34M
Codexis, Inc.
NASDAQ:CDXS
$218.15M
Coherus Oncology, Inc.
NASDAQ:CHRS
$171.37M
MediWound Ltd.
NASDAQ:MDWD
$154.46M
Protara Therapeutics, Inc.
NASDAQ:TARA
$150.50M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$94.98M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$64.96M
Who manages PLX?
Protalix BioTherapeutics, Inc. (PLX) lists 4 active executives. The top listed executive is Gilad Mamlok, Senior VP, CFO Treasurer & Secretary.
Are PLX insiders buying or selling?
Recent insider activity shows net selling of $22.07M.
Explore More
Continue the stock analysis
Jump to another research area for this company.